Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Philip P. Boudreau, EVP and CFO of Abbott Laboratories (ABT), filed a Form 4 reporting insider sales dated 08/08/2025. The filing lists a sale transaction reported at a weighted average price of $134.551 and notes transaction prices in the range $134.551 to $134.58. The table shows 5,550 shares sold (denoted D) and a direct beneficial ownership following the reported transaction of 51,003 shares. It also reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.
The Form 4 is signed on behalf of Mr. Boudreau by an attorney-in-fact and dated 08/11/2025. The filing includes an explicit offer to provide detailed per-price sale breakdowns upon request and discloses the reporting person’s title and relationship to the issuer. No additional financial metrics, forward-looking statements, or explanations of purpose for the sale are provided in the filing.
Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.
The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.